articleACS NanoJan 4, 2013Closed access

Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo

California NanoSystems Institute · University of California, Los Angeles

PubMed
Indexed incrossrefpubmed

Abstract

We used a multifunctional mesoporous silica nanoparticle (MSNP) carrier to overcome doxorubicin (Dox) resistance in a multidrug resistant (MDR) human breast cancer xenograft by codelivering Dox and siRNA that targets the P-glycoprotein (Pgp) drug exporter. The Pgp siRNA selection from among a series of drug resistance targets was achieved by performing high throughput screening in a MDR breast cancer cell line, MCF-7/MDR. Following the establishment of a MCF-7/MDR xenograft model in nude mice, we demonstrated that a 50 nm MSNP, functionalized by a polyethyleneimine-polyethylene glycol (PEI-PEG) copolymer, provides protected delivery of stably bound Dox and Pgp siRNA to the tumor site. The effective…

Citation impact

570
total citations
FWCI
34.75
Percentile
100%
References
46
Citations per year

Authors

11

Topics & keywords

Keywords
  • Nanocarriers
  • Doxorubicin
  • In vivo
  • Multiple drug resistance
  • Tumor microenvironment
  • Cancer research
  • Drug delivery
  • P-glycoprotein
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.